文献速递肺栓塞与肺血管病

肺动脉高压临床试验设计、终点与新兴治疗

Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension.
PubMed 文献 · Eur Respir J · 2024-10-31

本文为世界肺动脉高压研讨会工作组文章,讨论肺动脉高压(PAH)临床试验面临样本量、效率及在多重背景治疗下证明增量获益等挑战。文章涉及新兴试验终点与设计、生物标志物与替代终点验证、疾病修饰概念、多样性与代表性以及人工智能等新技术的应用。

要点

  • PAH三期试验主要终点须反映患者「感觉、功能或生存」。
  • 多重背景治疗下证明增量获益使未来试验面临样本量与效率挑战。
  • 新终点、新设计与新技术须兼顾患者与监管可接受性及方法学严谨性。

核心结论

  • 未来PAH试验需应对样本量、效率及在多重背景治疗人群中证明增量获益的挑战。
  • 新型终点、创新设计与统计方法及新技术可能是上述挑战的潜在解决方案。

研究设计与样本

  • 本文为世界肺动脉高压研讨会工作组文章,非原始研究,未报告样本量。

主要发现

  • PAH临床试验已促成多种有效治疗获批,改善症状、运动能力和临床结局。
  • 未来试验面临与样本量要求、效率及增量获益证明相关的挑战。

关键数值与推荐

  • PAH三期临床试验的主要终点必须反映患者「感觉、功能或生存」。
  • 替代终点需经验证,文中讨论生物标志物与替代终点验证。

临床怎么用

  • 文章讨论的新兴终点、设计与技术可为未来PAH试验设计提供参考。
  • 应用时需确保方案对患者和监管机构可接受并保持方法学严谨。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials in pulmonary arterial hypertension (PAH) have led to the approval of several effective treatments that improve symptoms, exercise capacity and clinical outcomes. In phase 3 clinical trials, primary end-points must reflect how a patient "feels, functions or survives". In a rare disease like PAH, with an ever-growing number of treatment options and numerous candidate therapies being studied, future clinical trials are now faced with challenges related to sample size requirements, efficiency and demonstration of incremental benefit on traditional end-points in patients receiving background therapy with multiple drugs. Novel clinical trial end-points, innovative trial designs and statistical approaches and new technologies may be potential solutions to tackle the challenges facing future PAH trials, but these must be acceptable to patients and regulatory bodies while preserving methodological rigour. In this World Symposium on Pulmonary Hypertension task force article, we address emerging trial end-points and designs, biomarkers and surrogate end-point validation, the concept of disease modification, challenges and opportunities to address diversity and representativeness, and the use of new technologies such as artificial intelligence in PAH clinical trials.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Weatherald J, Fleming TR, Wilkins MR, et al. Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension. Eur Respir J. 2024. PMID: 39209468. doi:10.1183/13993003.01205-2024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。